CM
IOVA icon

Capula Management’s Iovance Biotherapeutics IOVA Stock Holding History

Capula Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-140,060
Closed -$637K – 420
2023
Q3 		$637K Buy
140,060
+58,540
+72% +$382K 0.01% 300
2023
Q2 		$574K Buy
+81,520
New +$583K 0.01% 259

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Capula Management's IOVA Position: Q4 2023 in Review

Capula Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2023, closing a stake of 140,060 shares — an estimated $637K sold.

Capula Management first reported a position in IOVA in Q2 2023 and held it in 2 quarters. The position peaked at $637K in Q3 2023. 236 funds tracked by Wall St. Rank hold IOVA as of Q4 2023.

  • Capula Management reported no remaining Iovance Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Capula Management sold 140,060 Iovance Biotherapeutics shares in Q4 2023, an estimated $637K.
  • Capula Management first reported a position in Iovance Biotherapeutics in Q2 2023 and held it in 2 quarters.
  • Capula Management's Iovance Biotherapeutics position peaked at $637K in Q3 2023.
  • 236 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2023.

Based on Capula Management's 13F filing for Q4 2023, filed 12 Feb 2024.